A plain-spoken reading room for the semaglutide literature — the oral tablet and the once-weekly shot, side by side, from STEP 1 and SUSTAIN-6 to SELECT, FLOW and SURMOUNT-5.
Pharmacy Semaglutide

Semaglutide Effects, Side Effects and Safety: What People Report

The short version

This page is the honest two-sided story of semaglutide effects — the upsides people rave about and the downsides nobody warns you about loudly enough. The biggest reported benefit is simple: the constant background chatter about food, what people call "food noise," goes quiet. People say they feel full faster, crave sugar and greasy food less, and lose weight steadily over months. Many with type 2 diabetes report their blood-sugar numbers dropping into normal ranges.

The trade-offs are mostly digestive. Nausea is the single most common complaint, especially in the first weeks and after each dose increase; some people get sulfur-smelling "egg" burps, constipation or diarrhea, reflux, or early tiredness. Most of it eases as the body adjusts. Below we split this into two parts: first what the research-use community actually reports (clearly labeled as anecdote), then the safety cautions that are grounded in published studies and cited. No doses here, and nothing on this page is medical advice.

What people report

These are effects reported by people using semaglutide and posting in research-use and patient communities — anecdotal, not clinical evidence, and not verified by controlled trials. They line up with the trial data in broad strokes, but they are stories, not endpoints. No doses are attached to any of them.

The benefits people describe most

  • Quieter "food noise" (frequently reported). By far the most common thing people describe is that the constant mental chatter about food simply goes quiet, often within the first week or two. They feel full faster, eat a third to half of their old portions, and stop obsessing over the next meal. Many call this the single most life-changing effect.
  • Fewer cravings (frequently reported). Sweet-tooth and sugar cravings drop sharply or vanish, and fried, greasy, high-fat foods stop appealing — sometimes turning slightly off-putting. Several people say they naturally drift toward fruit, vegetables, and lighter meals.
  • Weight loss (frequently reported). The overwhelming majority report losing weight, often describing it as steady and substantial over several months, with the pace slowing after the early stretch. Many tie it directly to eating much less rather than to exercising more.
  • Better blood-sugar control (commonly reported). Among people using it for type 2 diabetes, a common theme is markedly improved blood-sugar and A1C readings, with some describing fasting numbers and long-term averages dropping into normal ranges.
  • Less interest in alcohol (occasionally reported). A recurring side observation is that the urge to drink fades along with food cravings — some people say they simply lose interest. (Interestingly, a rodent study found semaglutide reduced alcohol intake too [12], though that's animal data, not proof in people.)

The downsides people describe most

  • Nausea, sometimes with vomiting (frequently reported). The most-reported side effect, mentioned by roughly a third of reviewers; it peaks in the first weeks and after each dose increase, then often eases within a week or two. People say it flares after overeating or fatty meals, and manage it with smaller, lighter meals and plenty of water.
  • Sulfur or "egg" burps (commonly reported). A distinctive complaint: foul-smelling burps compared to rotten eggs or sulfur, often after a dose increase, sometimes with bloating and a sense of food sitting too long. Many describe them as embarrassing and note they show up more often than official lists suggest.
  • Bowel changes (commonly reported). Both extremes turn up, sometimes alternating — hard, infrequent stools on one end, diarrhea (worse right after a dose or rich food) on the other.
  • Acid reflux and heartburn (occasionally reported). Often alongside the burping and bloating, tracking with dose increases; some manage it with over-the-counter acid reducers.
  • Early fatigue (commonly reported). Tiredness and low energy, especially the day or two after an injection and during the first weeks, usually easing with time.
  • Food aversions and taste changes (occasionally reported). Active aversions to fatty or meaty foods, a metallic taste, and a heightened, sometimes nausea-triggering sensitivity to smells — likened to morning sickness. For a few, appetite is suppressed so far they must remind themselves to eat.
  • Hair shedding and a gaunter face (sometimes reported). A smaller group notices increased hair shedding a few months in, plus a thinner, more hollow face — both widely attributed to losing weight quickly rather than the drug itself, and the shedding usually described as temporary.
  • Headaches and dizziness (occasionally reported). Often early in a new dose and linked to not drinking enough or eating too little; staying hydrated reportedly helps.
  • Injection-site reactions (sometimes reported). Mild redness, itching, a small bump or tenderness where people inject — generally minor and short-lived.

Semaglutide side effects: safety and cautions

This section is the genuinely useful context — cautions grounded in published studies and approved labeling, each cited. It is editorial commentary on the safety record, not medical advice, and it carries no dosing.

Gastrointestinal intolerance, especially during dose increases. Nausea, vomiting, diarrhea and constipation are the dominant adverse effects in clinical trials and the leading reason people stop. In the STEP weight-management program these events were mostly mild-to-moderate and transient, clustered around the period when the dose is being stepped up; a dedicated safety review reported nausea in roughly one-third of patients [5]. This is clinical, not theoretical — the slowing of stomach emptying that causes the GI effects is part of how the drug works.

A boxed warning for thyroid C-cell tumors (history of medullary thyroid cancer or MEN-2). GLP-1 medicines carry a boxed warning derived from rodent studies, where C-cell tumors appeared at very high exposures. A dedicated safety review concluded that human data do not establish a clear increase in thyroid cancer from semaglutide, so the signal is best framed as unconfirmed in people [5]. Even so, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is treated as a reason not to use it, on the strength of the animal finding.

Acute pancreatitis (a class caution). Pancreatitis is a recognized class warning for GLP-1 medicines, and treatment is conventionally stopped if it's suspected. The same safety review notes that pancreatic-cancer signals remain ones for which firm conclusions can't yet be drawn because the numbers are low — a precaution, not a demonstrated risk increase [5].

Gallbladder and biliary disease. A dedicated safety review found an increased risk of gallstones (cholelithiasis) with semaglutide, attributed largely to the rate and amount of weight loss rather than direct drug toxicity — but the increase versus placebo is a real finding, not just theoretical [5].

Pre-existing diabetic retinopathy with rapid blood-sugar correction. In SUSTAIN-6, complications of diabetic retinopathy (an eye disease of diabetes) were significantly more frequent with semaglutide (HR 1.76; 95% CI 1.11-2.78), concentrated in people who already had retinopathy and whose blood sugar dropped quickly [2]. The leading interpretation is early worsening driven by the speed of correction, not direct harm to the eye — monitoring is advised when glucose is corrected fast [5].

Loss of lean (muscle) mass. Body-composition work in the STEP program found that part of the weight lost is lean mass, not just fat. Because rapid, large weight loss can erode muscle, this raises a sarcopenia (muscle-wasting) concern, especially in older adults, and has driven research into protein intake and resistance training [5]. The lean-mass loss is observed; the downstream muscle-wasting worry is a reasoned extrapolation.

Weight regain after stopping. Stopping semaglutide is followed by substantial regain — in the STEP 1 extension, participants regained a mean of about 11.6 percentage points of body weight within a year, and cardiometabolic gains drifted back toward baseline [1]. This frames obesity drug therapy as ongoing rather than a one-time fix.

Hair shedding with rapid weight loss. A pharmacovigilance analysis flagged a reporting signal for hair loss (alopecia), and a separate study linked telogen effluvium — a reversible, diffuse shedding — to the size and speed of weight loss [5]. The signal is most consistent with rapid-weight-loss shedding rather than a direct drug effect.

Pregnancy. Semaglutide is contraindicated in pregnancy per its labeling. Because its half-life is about a week — with effectively complete clearance only around five weeks after the last dose — guidance advises stopping well in advance of a planned pregnancy [5].

Compounded semaglutide: why it's different

Compounded semaglutide is semaglutide prepared by a compounding pharmacy rather than the approved, manufactured product — and the distinction matters for safety. During a federally declared shortage (roughly 2022 to early 2025), compounding pharmacies were permitted to produce semaglutide [5]. The FDA documented dosing errors, adverse events serious enough to require hospitalization, and products with unverified or non-pharmaceutical active ingredients during that period.

After the shortage was declared resolved in early 2025, the compounding pathways were curtailed, leaving ongoing regulatory and telehealth uncertainty [5]. The short version: compounded or non-pharmaceutical sources fall outside the approved-product evidence base that every trial on this site is built on, and they carry documented quality and safety concerns. This is context for reading the research, not advice about what to take.

Then and now

Semaglutide is a recent medicine with a fast-moving history. It grew out of Novo Nordisk's earlier GLP-1 work and was engineered for once-weekly dosing through DPP-4 resistance and albumin-binding [5]. It first reached FDA approval for type 2 diabetes in 2017, the oral once-daily tablet followed in 2019-2020, and a chronic weight-management indication arrived in 2021 [1]. Its cardiovascular-outcomes evidence (SELECT) read out in 2023 [3] and its kidney-outcomes evidence (FLOW) in 2024 [6], with the corresponding heart and kidney indications approved in 2024-2025; a liver-disease (MASH) indication followed in 2025. It has never been an old, withdrawn, or grandfathered drug — its whole record is modern and trial-anchored.